Mibiton investment in the spotlight: State-of-the-art Bioreactor @Ncardia

Ncardia is an innovative stem cell drug discovery and development company, aiming at delivering safe and better medicines to patients faster. Using the Mibiton Solo fund, NCardia acquired a state-of-the-art Bioreactor system, which is now used to cultivate high quality 'hiPSC' cells. Read more.      

 

NCardia2018

 

Afdrukken